InChIKey	OLAHOMJCDNXHFI-UHFFFAOYSA-N
Compound Name	Erdafitinib
Canonical SMILES	COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1
Clinical Status	Data-mined Candidate
Targets (Human+Pathogen)	6
Pfam Stratification	Cross-Family
Avg pChEMBL	7.99
Source	ChEMBL;BindingDB

DrugBank ID	DB12147
Drug Name	Erdafitinib
CAS Number	1346242-81-6
Groups	approved investigational
ATC Codes	L01EN01
Description	In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2...

---

Categories: Antineoplastic Agents Antineoplastic and Immunomodulating Agents Cytochrome P-450 CYP2C9 Substrates Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index Cytochrome P-450 CYP3A Inducers Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Inducers Cytochrome P-450 CYP3A4 Inducers (strength unknown) Cytochrome P-450 CYP3A4 Inhibitors Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index Cytochrome P-450 Enzyme Inducers Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 Substrates Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors Heterocyclic Compounds, Fused-Ring Kinase Inhibitor Narrow Therapeutic Index Drugs OCT2 Inhibitors P-glycoprotein inhibitors P-glycoprotein substrates P-glycoprotein substrates with a Narrow Therapeutic Index Protein Kinase Inhibitors Receptors, Fibroblast Growth Factor, antagonists & inhibitors Tumor Suppressor Proteins Tyrosine Kinase Inhibitors

---

Cross-references: BindingDB: 50525939 CHEMBL3545376 ChemSpider: 35308353 Drugs Product Database (DPD): 23382 PDB: 5SF PubChem:67462786 PubChem:347828443 RxCUI: 2123125 Wikipedia: Erdafitinib ZINC: ZINC000168520308